INVA Q4 2022 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M-38.9% YoY

Gross Profit

$53M80.5% margin

Operating Income

$31M46.9% margin

Net Income

-$68M-103.8% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

-2.2%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$666M

Stockholders' Equity

$566M

Cash & Equivalents

$291M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$108M	-38.9%
Gross Profit	$53M	$108M	-50.8%
Operating Income	$31M	$105M	-70.5%
Net Income	-$68M	$10M	-760.4%

Revenue Segments

Royalty

$51M78%

Product

$15M22%